Table 2.

Comparison of changes after PAE on large volume (PV ≥80 mL) BPH with baseline⁹–¹²

Variables	1 month		3 months		6 months		12 months
	MD (95% CI)	P-value	MD (95% CI)	P-value	MD (95% CI)	P-value	MD (95% CI)	P-value
IPSSs	−15.97 (−17.25 to −14.68)	<0.00001	−17.97 (−19.00 to −16.94)	<0.00001	−18.61 (−19.74 to −17.48)	<0.00001	−18.32 (−19.54 to −17.09)	<0.00001
QoL scores	−2.51 (−2.74 to −2.29)	<0.00001	−2.64 (−3.30 to −1.98)	<0.00001	−2.45 (−3.10 to −1.80)	<0.00001	−2.50 (−2.83 to −2.17)	<0.00001
PV	−13.11 (−20.63 to −5.60)	0.0006	−43.39 (−49.92 to −36.85)	<0.00001	−47.05 (−53.50 to −40.60)	<0.00001	−47.58 (−53.94 to −41.21)	<0.00001
PSA	−0.23 (−1.21 to 0.74)	0.64	−0.45 (−1.41 to −0.52)	0.36	−0.74 (−1.15 to −0.33)	0.0004	−0.42 (−0.82 to −0.03)	0.04
Qmax	5.42 (4.73 to 6.12)	<0.00001	6.66 (5.9 to 7.43)	<0.00001	7.00 (5.95 to 8.05)	<0.00001	6.00 (5.14 to 6.86)	<0.00001
PVR volume	−76.64 (−84.98 to −68.29)	<0.00001	−82.73 (−91.10 to −74.36)	<0.00001	−88.35 (−96.39 to −80.31)	<0.00001	−76.80 (−121.87 to −31.72)	0.0008
IIEF-5 scores	−0.04 (−1.31 to 1.22)	0.95	−0.65 (−1.93 to 3.23)	0.62	0.85 (−1.70 to 3.41)	0.51	−0.24 (−5.12 to 4.63)	0.92

Note: Data from Isaacson et al,⁹ Bagla et al,¹⁰ Li et al,¹¹ and Wang et al.¹²

Abbreviations: BPH, benign prostatic hyperplasia; CI, confidence interval; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; MD, mean difference; PAE, prostate artery embolization; PSA, prostate-specific antigen; PV, prostate volume; PVR, postvoid residual; Q_max, peak urinary flow rate; QoL, quality of life.